Back to Search Start Over

Inhibition of the activation of Hageman factor (factor XII) by peripheral blood cells.

Authors :
Ratnoff OD
Emanuelson MM
Ziats NP
Source :
The Journal of clinical investigation [J Clin Invest] 1987 Oct; Vol. 80 (4), pp. 1180-9.
Publication Year :
1987

Abstract

Suspensions of peripheral blood mononuclear cells (PBMC), monocytes, T or B lymphocytes, platelets or granulocytes, and cell-depleted supernatant fluids of these suspensions inhibited activation of Hageman factor (HF, Factor XII) by ellagic acid, a property not shared by erythrocytes. PBMC also inhibited HF activation by glass or sulfatides. Contaminating platelets may have contributed to inhibition by PBMC. Elaboration of agents inhibiting HF activation required metabolically active cells. The inhibitor(s) in PBMC supernates were not identified with known agents, but had properties of a nonenzymatic protein. PBMC supernates did not contain fibrinogen, nor alter the thrombin, prothrombin, or partial thromboplastin times of normal plasma, amidolysis by activated plasma thromboplastin antecedent (Factor XIa) or activated Stuart factor (Factor Xa) or esterolysis by C1 (C1 esterase); they inhibited plasmin minimally. These experiments suggest that peripheral blood cells may impede intravascular coagulation. Whether this property helps maintain the fluidity of blood is unclear.

Details

Language :
English
ISSN :
0021-9738
Volume :
80
Issue :
4
Database :
MEDLINE
Journal :
The Journal of clinical investigation
Publication Type :
Academic Journal
Accession number :
3498741
Full Text :
https://doi.org/10.1172/JCI113177